Fayette Dan, Juríčková Veronika, Fajnerová Iveta, Horáček Jiří, Kozák Tomáš
National Institute of Mental Health, Topolová 748, 25067 Klecany, Czech Republic.
Third Faculty of Medicine, Charles University, Ruská 87, Prague 10, 10100 Prague, Czech Republic.
Cancers (Basel). 2025 Apr 28;17(9):1488. doi: 10.3390/cancers17091488.
BACKGROUND/OBJECTIVES: Cancer- or chemotherapy-related cognitive deficit is a common side effect occurring in patients with Hodgkin lymphoma. No previous study compared the influence of different types of treatment on the onset and development of chemotherapy cognitive impairment in longitudinal design. The aim of this study was to assess whether a more intensive form of chemotherapy causes greater cognitive impairment.
Forty-four patients at three different stages of the disease and with three different treatments (ABVD + 30 Gy, BEACOPPesc, or ABVD + 30 Gy plus BEACOPPesc) completed the neuropsychological battery and psychological measures of affective distress and quality of life. We compared their cognitive performance before, immediately after, and 6 months after the treatment.
Whether or not we divided the total number of people with Hodgkin lymphoma into two groups (mild and moderate disease versus severe disease) or three groups (mild, moderate, and advanced disease), we found no statistically significant difference between the groups in cognitive performance or other psychological factors or experienced quality of life.
Our results did not show that disease stage or treatment protocol had an effect on the depth of cognitive impairment in cancer or chemotherapy. We hypothesize that, in terms of brain health, intensive forms of chemotherapy (6 × BEA-COPPesc) do not pose a greater risk than milder forms (4 × ABVD + 30 Gy IF RT and 2 × BEACOPPesc + 4 × ABVD + 30 Gy IF RT) of cancer treatment for Hodgkin lymphoma. However, a limitation of our study is the small number of participants in the study, so it would be advisable to repeat the study on a larger sample of patients. Confirmation of our results could be beneficial in that neither patients nor physicians need to worry that intensive chemotherapy will worsen cognitive deficits.
背景/目的：癌症或化疗相关的认知缺陷是霍奇金淋巴瘤患者常见的副作用。以前没有研究在纵向设计中比较不同类型治疗对化疗认知障碍的发生和发展的影响。本研究的目的是评估更强化的化疗形式是否会导致更严重的认知障碍。
44例处于疾病三个不同阶段且接受三种不同治疗（ABVD + 30 Gy、BEACOPPesc或ABVD + 30 Gy加BEACOPPesc）的患者完成了神经心理测试以及情感痛苦和生活质量的心理测量。我们比较了他们在治疗前、治疗后立即以及治疗后6个月的认知表现。
无论我们将霍奇金淋巴瘤患者总数分为两组（轻度和中度疾病与重度疾病）还是三组（轻度、中度和晚期疾病），我们发现各组在认知表现、其他心理因素或生活质量体验方面均无统计学上的显著差异。
我们的结果并未表明疾病阶段或治疗方案对癌症或化疗中认知障碍的深度有影响。我们推测，就大脑健康而言，强化化疗形式（6×BEA-COPPesc）对霍奇金淋巴瘤的癌症治疗并不比温和形式（4×ABVD + 30 Gy IF RT和2×BEACOPPesc + 4×ABVD + 30 Gy IF RT）带来更大风险。然而，我们研究的一个局限性是研究参与者数量较少，因此建议在更大的患者样本上重复该研究。对我们结果的确认可能是有益的，因为患者和医生都无需担心强化化疗会使认知缺陷恶化。
